EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Psilocybin in pharmacotherapy of obsessive-compulsive disorder

Maja Owe-Larsson, Katarzyna Kamińska, Barbara Buchalska, Dagmara Mirowska-Guzel, Agnieszka Cudnoch-Jędrzejewska

Pharmacological Reports · 2024

DOI: 10.1007/s43440-024-00633-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Reports, 2024. Verfasst von Maja Owe-Larsson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Center for Preclinical Research, Department of Experimental and Clinical Physiology, Medical University of Warsaw, Banacha 1B, Warszawa…. Hauptthemen laut MEDLINE: Obsessive-Compulsive Disorder, Psilocybin, Hallucinogens. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsions are troublesome for patients and may disturb their everyday activities. The pathogenesis of this disease is still not fully elucidated, but dysfunctions of serotonin-, dopamine- and glutamate-mediated neurotransmission together with early maladaptive schemas seem of importance. Pharmacological treatment includes drugs affecting the serotoninergic, dopaminergic, and glutamatergic systems, such as selective serotonin reuptake inhibitors (SSRIs). Providing that up to 40% of patients with OCD are resistant to the currently available medications, there is a need for novel and effective therapies. Recent discoveries suggest that psilocybin, a non-physically addictive psychoactive substance, may ameliorate disease symptoms. When used in appropriate doses and under strict clinical control, psilocybin appears as a valuable treatment for OCD. This narrative article provides a thorough overview of OCD’s etiology, current treatment options, and the emerging evidence supporting psilocybin’s efficacy in managing OCD symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Obsessive-Compulsive DisorderPsilocybinHallucinogensHumansSelective Serotonin Reuptake InhibitorsAnimals

Stichwörter der Autor:innen

Obsessive-compulsive disorderPsilocinPsilocybinSerotonin

Substanzen

PsilocybinHallucinogensSelective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Laboratory of Center for Preclinical Research, Department of Experimental and Clinical Physiology, Medical University of Warsaw, Banacha 1B, Warszawa, 02-097, Poland. maja.owelarsson@gmail.com.
  • Laboratory of Center for Preclinical Research, Department of Experimental and Clinical Physiology, Medical University of Warsaw, Banacha 1B, Warszawa, 02-097, Poland. katarzyna.kaminska@wum.edu.pl.
  • Laboratory of Center for Preclinical Research, Department of Experimental and Clinical Physiology, Medical University of Warsaw, Banacha 1B, Warszawa, 02-097, Poland.
  • Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warszawa, Poland.

Zitieren

APA

Owe-Larsson, M., Kamińska, K., Buchalska, B., Mirowska-Guzel, D., & Cudnoch-Jędrzejewska, A. (2024). Psilocybin in pharmacotherapy of obsessive-compulsive disorder. Pharmacological Reports. https://doi.org/10.1007/s43440-024-00633-1

Vancouver

Owe-Larsson M, Kamińska K, Buchalska B, Mirowska-Guzel D, Cudnoch-Jędrzejewska A. Psilocybin in pharmacotherapy of obsessive-compulsive disorder. Pharmacological Reports. 2024. doi:10.1007/s43440-024-00633-1

BibTeX
@article{OweLarsson2024,
  author = {Owe-Larsson, Maja and Kamińska, Katarzyna and Buchalska, Barbara and Mirowska-Guzel, Dagmara and Cudnoch-Jędrzejewska, Agnieszka},
  title = {Psilocybin in pharmacotherapy of obsessive-compulsive disorder},
  journal = {Pharmacological Reports},
  year = {2024},
  doi = {10.1007/s43440-024-00633-1}
}
Kostenlos starten →